Egyptian International Pharmaceutical Industries Company produces and sells pharmaceuticals primarily in Egypt.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م43.00|
|52 Week High||ج.م39.00|
|52 Week Low||ج.م50.98|
|1 Month Change||-7.13%|
|3 Month Change||-4.49%|
|1 Year Change||-8.51%|
|3 Year Change||-51.14%|
|5 Year Change||-20.96%|
|Change since IPO||668.99%|
Recent News & Updates
|PHAR||EG Pharmaceuticals||EG Market|
Return vs Industry: PHAR underperformed the EG Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: PHAR underperformed the EG Market which returned 10.9% over the past year.
Stable Share Price: PHAR is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PHAR's weekly volatility (4%) has been stable over the past year.
About the Company
Egyptian International Pharmaceutical Industries Company produces and sells pharmaceuticals primarily in Egypt. It produces various dosage forms, such as the spansule capsules, soft gelatin capsules, lyophilized products, gels, sprayers, and effervescent tablets. The company’s products include anaesthetics, antibiotics, antifungals, antihistaminic products, antiparasitic products, antiviral products, blood-forming drugs, cardiovascular drugs, dental products, dermatology products, gastrointestinal drugs, genitourinary system drugs, hospital products, musculoskeletal drugs, nervous system drugs, ophthalmic products, oral antidiabetic products, psychiatry drugs, pulmonics, systemic corticosteroids, systemic hormones, vitamins, electrolytes and combinations, and other products, as well as analgesics, antipyretics, and anticatarrhal drugs.
Egyptian International Pharmaceutical Industries Fundamentals Summary
|PHAR fundamental statistics|
Is PHAR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHAR income statement (TTM)|
|Cost of Revenue||ج.م1.70b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.99|
|Net Profit Margin||16.30%|
How did PHAR perform over the long term?See historical performance and comparison
Is Egyptian International Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHAR (EGP43) is trading below our estimate of fair value (EGP59.1)
Significantly Below Fair Value: PHAR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHAR is poor value based on its PE Ratio (8.6x) compared to the EG Pharmaceuticals industry average (5.7x).
PE vs Market: PHAR is good value based on its PE Ratio (8.6x) compared to the EG market (11.9x).
Price to Earnings Growth Ratio
PEG Ratio: PHAR is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: PHAR is overvalued based on its PB Ratio (1.5x) compared to the EG Pharmaceuticals industry average (1.3x).
How is Egyptian International Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHAR's forecast earnings growth (13.9% per year) is above the savings rate (9.1%).
Earnings vs Market: PHAR's earnings (13.9% per year) are forecast to grow slower than the EG market (14.3% per year).
High Growth Earnings: PHAR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHAR's revenue (13.7% per year) is forecast to grow faster than the EG market (10% per year).
High Growth Revenue: PHAR's revenue (13.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHAR's Return on Equity is forecast to be high in 3 years time (26.1%)
How has Egyptian International Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHAR has high quality earnings.
Growing Profit Margin: PHAR's current net profit margins (16.3%) are lower than last year (17.2%).
Past Earnings Growth Analysis
Earnings Trend: PHAR's earnings have declined by 0.3% per year over the past 5 years.
Accelerating Growth: PHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHAR had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: PHAR's Return on Equity (17.7%) is considered low.
How is Egyptian International Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: PHAR's short term assets (EGP3.6B) exceed its short term liabilities (EGP2.1B).
Long Term Liabilities: PHAR's short term assets (EGP3.6B) exceed its long term liabilities (EGP56.0M).
Debt to Equity History and Analysis
Debt Level: PHAR's debt to equity ratio (65.2%) is considered high.
Reducing Debt: PHAR's debt to equity ratio has increased from 0.2% to 65.2% over the past 5 years.
Debt Coverage: PHAR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PHAR's interest payments on its debt are well covered by EBIT (7.9x coverage).
What is Egyptian International Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHAR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHAR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PHAR is not paying a notable dividend for the EG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHAR's dividend in 3 years as they are not forecast to pay a notable one for the EG market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Ahmed Said Kelani serves as the Chairman of the Board and Managing Director at Egyptian International Pharmaceutical Industries Company.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Egyptian International Pharmaceutical Industries Company's employee growth, exchange listings and data sources
- Name: Egyptian International Pharmaceutical Industries Company
- Ticker: PHAR
- Exchange: CASE
- Founded: 1980
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م4.264b
- Shares outstanding: 99.17m
- Website: https://www.eipico.com.eg
- Egyptian International Pharmaceutical Industries Company
- 1st Industrial Zone B1
- 10th of Ramadan City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 14:32|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.